Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development Portfolio News / Karina Tin May 26, 2022 Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development Read More »
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy Portfolio News / Karina Tin May 26, 2022 Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy Read More »
RAPT Therapeutics Announces Private Placement Financing of $50 Million Portfolio News / Karina Tin May 25, 2022 RAPT Therapeutics Announces Private Placement Financing of $50 Million Read More »
NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022 Portfolio News / Karina Tin May 24, 2022 NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022 Read More »
RAPT Therapeutics Announces Initiation of Phase 2B Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis Portfolio News / Karina Tin May 23, 2022 RAPT Therapeutics Announces Initiation of Phase 2B Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis Read More »
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis Portfolio News / Karina Tin May 18, 2022 Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis Read More »
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas Portfolio News / Karina Tin May 17, 2022 Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas Read More »
Kallyope and Sosei Heptares Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery Portfolio News / Karina Tin May 17th, 2022 Kallyope and Sosei Heptares Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery Read More »
Remix Therapeutics Closes $70 Million Series B Financing Portfolio News / Karina Tin May 17, 2022 Remix Therapeutics Closes $70 Million Series B Financing Read More »
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease Portfolio News / Karina Tin May 16, 2022 Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease Read More »
